Clinical outcomes of resected EGFR positive stage I-III NSCLC patients in the Midlands, UK

被引：0
|
作者：
Powell, R. L. [1 ]
Murukesh, N. [2 ]
Seeva, P. [2 ]
Solanki, A. [3 ]
Singh, A. [3 ]
Jain, A. [4 ]
Elmasry, A. R. [5 ]
Jegannathen, A. [5 ]
Irwin, A. [6 ]
Ghafoor, Q. [6 ]
O'Sullivan, B. [6 ]
Taniere, P. [7 ]
Baijal, S. [8 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Clin Haematol & Oncol Dept, Heartlands Hosp, Birmingham, W Midlands, England
[2] Worcestershire Royal Hosp, Dept Oncol, Worcester, England
[3] Royal Wolverhampton NHS Trust, New Cross Hosp, Deanesly Ctr, Wolverhampton, England
[4] New Cross Hosp, Royal Wolverhampton Hosp NHS Trust, Wolverhampton, England
[5] Univ Hosp North Midlands, Stoke On Trent, Staffs, England
[6] New Queen Elizabeth Hosp Birmingham, Oncol, Birmingham, W Midlands, England
[7] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England
[8] Heart England NHS Fdn Trust, Heartlands Hosp, Birmingham, W Midlands, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
67P
引用
收藏
页码：S731 / S732
页数：2
相关论文
共 50 条
  • [1] Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR
    Dao, T. V.
    Soo, R. A.
    Batra, U.
    Tamayo, M. B. E.
    Tejado Gallegos, L. F.
    Donner, N.
    Alsayed, M.
    Huggenberger, R.
    Reungwetwattana, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S271 - S271
  • [2] Demographics, clinical characteristics, treatment patterns and clinical outcomes of patients with stages I-III resected NSCLC without known EGFR mutations
    Altorki, N. K.
    Salomonsen, R.
    Georgoulia, N. E.
    Perez, I. Diaz
    Wang, A.
    Cai, L.
    Wetherill, G.
    Xiao, Y.
    Fielden, C.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S975 - S975
  • [3] Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAM
    Amorin, E.
    Perroud, H. A.
    Hellal, L. G-H.
    Francisco, S. V.
    Guerrero, A. P.
    Vasquez, A.
    Gallegos, L. F. T.
    Donner, N.
    Huggenberger, R.
    Corrales, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S739 - S739
  • [4] Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study.
    Soo, Ross A.
    Reungwetwattana, Thanyanan
    Perroud, Herman Andres
    Batra, Ullas
    Kilickap, Saadettin
    Gallegos, Luis Fernando Tejado
    Donner, Natalia
    Alsayed, Mohamed
    Huggenberger, Reto
    Dao, Tu Van
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
    Chia, P. L.
    Chung, J. T. Kit
    Asmat, A.
    Huggenberger, R.
    Verma, A.
    Soo, R. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1649 - S1650
  • [6] Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
    Chaft, Jamie E.
    Costa, Daniel Botelho
    Muzikansky, Alona
    Shrager, Joseph B.
    Lanuti, Michael
    Huang, James
    Ramchandran, Kavitha
    Rangachari, Deepa
    Huberman, Mark
    Piotrowska, Zofia
    Kris, Mark G.
    Azzoli, Christopher G.
    Sequist, Lecia V.
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
    Schmid, S.
    Garcia, M.
    Hueniken, K.
    Balaratnam, K.
    Patel, D.
    Zhan, L.
    Brown, M. C.
    Sacher, A.
    Bradbury, P.
    Leighl, N.
    Shepherd, F. A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S945 - S945
  • [8] Radiotherapy for Patients with Stage I-III NSCLC in a geriatric Cllective - A monocentric Analysis
    Alt, N.
    Muster, J.
    Rieken, S.
    Leu, M.
    Habermann, F. -N.
    Droege, L.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S147 - S148
  • [9] IS THERE A ROLE FOR TARGETED AGENTS OR BIOLOGICALS IN STAGE I-III NSCLC?
    Gautschi, O.
    ANNALS OF ONCOLOGY, 2012, 23 : 49 - 49
  • [10] Tumor infiltrating T cells influence prognosis in stage I-III NSCLC patients
    Schulze, A. B.
    Evers, G.
    Goerlich, D.
    Mohr, M.
    Marra, A.
    Hillejan, L.
    Rehkaemper, J.
    Heitkoetter, B.
    Schmidt, L. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 138 - 138
12345